We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Schrodinger Inc (SDGR) USD0.01

Sell:$24.29 Buy:$24.32 Change: $0.1 (0.41%)
NASDAQ:2.05%
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
Sell:$24.29
Buy:$24.32
Change: $0.1 (0.41%)
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
Sell:$24.29
Buy:$24.32
Change: $0.1 (0.41%)
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor). Its software was used by researchers around the world at more than 1,760 academic institutions.

Contact details

Address:
1540 BROADWAY, 24TH FLOOR
NEW YORK
10036
United States
Telephone:
+1 (503) 2991150
Website:
https://www.schrodinger.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SDGR
ISIN:
US80810D1037
Market cap:
$1.81 billion
Shares in issue:
72.31 million
Sector:
Health Care Technology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Ramy Farid
    President, Chief Executive Officer, Director
  • Geoffrey Porges
    Chief Financial Officer, Executive Vice President
  • Karen Akinsanya
    President - R&D Therapeutics
  • Kenneth Lorton
    Executive Vice President, Chief Technology Officer
  • Yvonne Tran
    Executive Vice President, Chief Legal Officer, Corporate Secretary
  • Robert Abel
    Executive Vice President, Chief Computational Scientist, Head of Modeling Research and Development
  • Margaret Dugan
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.